Femasys Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
Rhea-AI Summary
Femasys (NASDAQ: FEMY) said Nasdaq granted a 180-calendar day extension on January 13, 2026 to regain compliance with the minimum $1.00 bid price requirement.
The company has until July 13, 2026 to achieve a closing bid of $1.00 or higher for at least ten consecutive business days to regain compliance. Nasdaq noted Femasys meets the market value of publicly held shares and other initial listing requirements, except the bid price rule. Femasys said it may effect a reverse stock split, if necessary, and will monitor its share price and take actions within the prescribed period to regain compliance.
Positive
- Nasdaq granted a 180-day compliance extension to July 13, 2026
- Nasdaq confirmed compliance with market value and other listing requirements
Negative
- Common stock bid price below the $1.00 minimum as of Jan 13, 2026
- Company may effect a reverse stock split, which could affect liquidity
- Must achieve $1.00 close for ten consecutive business days by July 13, 2026
News Market Reaction – FEMY
In the Jan 14 session, FEMY gained 17.81%, reflecting a significant positive market reaction. Argus tracked a peak move of +14.0% during that session. Our momentum scanner triggered 27 alerts that day, indicating elevated trading interest and price volatility. Trading volume was above average at 1.7x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Oct 22 | PMS study initiation | Positive | -9.6% | Launch of EU post-market surveillance study for FemBloc permanent birth control. |
| Nov 03 | FDA IDE & financing | Positive | +3.1% | FDA IDE approval for FemBloc trial and $12M secured convertible note financing. |
| Nov 10 | European commercial order | Positive | +0.0% | Initial FemBloc commercial order in France and Benelux via Kebomed. |
| Nov 14 | Q3 results & update | Positive | +8.6% | 3Q25 results with sales growth, new approvals and strengthened liquidity. |
| Dec 18 | FDA 510(k) clearance | Positive | +4.1% | U.S. FDA 510(k) clearance for next‑generation FemVue diagnostic device. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent FDA and financing milestones generally saw positive or flat reactions, with one notable selloff on otherwise constructive clinical news.
Over the past few months, Femasys reported multiple regulatory and commercial milestones, including FDA IDE approval and financing with potential proceeds up to $58 million on Nov 3, 2025, a European FemBloc order around $500,000 on Nov 10, 2025, and 3Q25 sales of $729,394 reported on Nov 14, 2025. FDA 510(k) clearance for the next‑generation FemVue device followed on Dec 18, 2025. Against this backdrop of clinical and commercial progress, the new Nasdaq bid-price extension addresses ongoing listing compliance tied to the stock’s low trading price.
Key Terms
reverse stock split financial
minimum closing bid price requirement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
ATLANTA, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (“Femasys” or the “Company”), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, today announced that on January 13, 2026, it received notification from The Nasdaq Stock Market LLC ("Nasdaq") that Nasdaq approved the Company's request for an additional 180-calendar day extension to regain compliance with the minimum closing bid price requirement of US
Nasdaq's extension notice has no immediate effect on the continued listing status of the Company's common stock on The Nasdaq Capital Market LLC under the symbol "FEMY". If at any time during the additional 180-day extension, the bid price of the Company's common stock closes at, or above,
Femasys remains committed to full compliance with all Nasdaq listing requirements and will continue to monitor its share price closely. The Company plans to take all necessary actions within the prescribed period to regain compliance.
About Femasys
Femasys is a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide through its broad, patent-protected portfolio of novel, in-office therapeutic and diagnostic products. As a U.S. manufacturer with global regulatory approvals, Femasys is actively commercializing its lead product innovations in the U.S. and key international markets. Femasys’ fertility portfolio includes FemaSeed® Intratubal Insemination, a groundbreaking first-step infertility treatment and FemVue®, a companion diagnostic for fallopian tube assessment. Published clinical trial data demonstrates FemaSeed is over twice as effective as traditional IUI, with a comparable safety profile, and high patient and practitioner satisfaction.1
FemBloc® permanent birth control is the first and only non-surgical, in-office alternative to centuries-old surgical sterilization that received full regulatory approval in Europe in June of 2025, the UK in August 2025, and New Zealand in September 2025. Commercialization of this highly cost-effective, convenient and significantly safer approach will be completed through strategic partnerships in select European countries. Alongside FemBloc, the FemChec®, diagnostic product provides an ultrasound-based test to confirm procedural success. Published data from initial clinical trials demonstrated compelling effectiveness, five-year safety, and high patient and practitioner satisfaction.2 For U.S. FDA approval, enrollment in the FINALE pivotal trial (NCT05977751) is on-going.
Learn more at www.femasys.com, or follow us on X, Facebook and LinkedIn.
References
1Liu, J. H., Glassner, M., Gracia, C. R., Johnstone, E. B., Schnell, V. L., Thomas, M. A., L. Morrison, Lee-Sepsick, K. (2024). FemaSeed Directional Intratubal Artificial Insemination for Couples with Male-Factor or Unexplained Infertility Associated with Low Male Sperm Count. J Gynecol Reprod Med, 8(2), 01-12. doi: 10.33140/JGRM.08.02.08.
2Liu, J. H., Blumenthal, P. D., Castaño, P. M., Chudnoff, S. C., Gawron, L. M., Johnstone, E. B., Lee-Sepsick, K. (2025). FemBloc Non-Surgical Permanent Contraception for Occlusion of the Fallopian Tubes. J Gynecol Reprod Med, 9(1), 01-12. doi: 10.33140/JGRM.09.01.05.
Forward-Looking Statements
This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “suggests,” “potential,” “hope,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to obtain regulatory approvals for our FemBloc product candidate; develop and advance our current FemBloc product candidate and successfully enroll and complete the clinical trial; the ability of our clinical trial to demonstrate safety and effectiveness of our product candidate and other positive results; estimates regarding the total addressable market for our products and product candidate; our ability to commercialize our products and product candidate, our ability to establish, maintain, grow or increase sales and revenues, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.
Contacts:
David Gutierrez, Dresner Corporate Services, (312) 780-7204, dgutierrez@dresnerco.com
Nathan Abler, Dresner Corporate Services, (714) 742-4180, nabler@dresnerco.com
